Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Endocrinology

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.17925/EE.2014.10.02.111PMID 29872474PMCID PMC5983079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study].

  2014cited by this paper
• Five-Month Observation of Persistent Diabetic Macular Edema after Intravitreal Injection of Ozurdex Implant

  2014cited by this paper
• Fluocinolone Acetonide Intravitreal Implant (Iluvien®)

  2013cited by this paper
• Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

  2013cited by this paper
• Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema

  2013cited by this paper
• Diabetic macular edema: New promising therapies.

  2013cited by this paper
• Global Prevalence and Major Risk Factors of Diabetic Retinopathy

  2012cited by this paper
• Short-term results of intravitreal dexamethasone implant (OZURDEX®) in treatment of recalcitrant diabetic macular edema: A case series

  2012cited by this paper
• Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema

  2012cited by this paper
• Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.

  2011cited by this paper
• Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system

  2011cited by this paper
• [Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema].

  2011cited by this paper
• Fluocinolone acetonide implantable device for diabetic retinopathy.

  2011cited by this paper
• Sustained-release dexamethasone intravitreal implant for treatment of diabetic macular edema

  2011cited by this paper
• Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?

  2011cited by this paper
• The Role of Steroids in the Management of Uveitic Macular Edema

  2011cited by this paper
• DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS

  2011cited by this paper
• Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema

  2011cited by this paper
• Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

  2011cited by this paper
• Dexamethasone for ocular inflammation

  2011cited by this paper
• Intravitreal Injection of Commercially Available Ketorolac Tromethamine in Eyes with Diabetic Macular Edema Refractory to Laser Photocoagulation

  2011cited by this paper
• Prevalence of diabetes among men and women in China.

  2010cited by this paper
• Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema.

  2010cited by this paper
• Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

  2010cited by this paper
• Intravitreous dexamethasone effects on different patterns of diabetic macular edema.

  2010cited by this paper
• Intravitreal bevacizumab for the treatment of refractory diabetic macular edema.

  2010cited by this paper
• Prevalence of diabetes among men and women in China.

  2010cited by this paper
• Pars Plana Vitrectomy with Internal Limiting Membrane Peeling for Refractory Diffuse Diabetic Macular Edema

  2010cited by this paper
• Refractory Diabetic Macular Edema

  2010cited by this paper
• Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)

  2010cited by this paper
• Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.

  2010cited by this paper
• Biodegradable Intraocular Therapies for Retinal Disorders

  2010cited by this paper
• Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

  2010cited by this paper
• Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

  2010cited by this paper
• Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

  2010cited by this paper
• Recent advances in ophthalmic drug delivery.

  2010cited by this paper
• Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone.

  2009cited by this paper
• EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMA

  2009cited by this paper
• Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression.

  2008cited by this paper
• Iluvien: a new sustained delivery technology for posterior eye disease.

  2008cited by this paper
• Iluvien™: a new sustained delivery technology for posterior eye disease

  2008cited by this paper
• Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.

  2007cited by this paper
• Overview of epidemiologic studies of diabetic retinopathy.

  2007cited by this paper
• Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

  2007cited by this paper
• Glucocorticoids and cardiovascular disease.

  2007cited by this paper
• Standards of Medical Care in Diabetes: Response to Power

  2006cited by this paper
• Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema.

  2006cited by this paper
• Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.

  2006cited by this paper
• Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.

  2006cited by this paper
• Corticosteroid effects on cell signalling

  2006cited by this paper
• Treating Chronic Noninfectious Posterior Segment Uveitis: The Impact of Cumulative Damage Proceedings of an Expert Panel Roundtable Discussion

  2006cited by this paper
• Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1

  2006cited by this paper
• Retisert (Bausch & Lomb/Control Delivery Systems).

  2005cited by this paper
• Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies.

  2005cited by this paper
• DIFFERENCE IN CLEARANCE OF INTRAVITREAL TRIAMCINOLONE ACETONIDE BETWEEN VITRECTOMIZED AND NONVITRECTOMIZED EYES

  2005cited by this paper
• Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisert™ Intravitreal Implantation in Rabbits Over a 1-Year Period

  2004cited by this paper
• Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models

  2003cited by this paper
• Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.

  2003cited by this paper
• Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.

  2003cited by this paper
• Glucocorticoids: do we know how they work?

  2002cited by this paper
• Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

  2002cited by this paper
• Biodegradable microspheres for vitreoretinal drug delivery.

  2001cited by this paper
• Cystoid macular edema following cataract surgery.

  2000cited by this paper
• Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.

  2000cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM.

  1998cited by this paper
• Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells.

  1998cited by this paper
• Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS

  1998cited by this paper
• Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.

  1997cited by this paper
• Ganciclovir implants: one year later.

  1997cited by this paper
• Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor

  1997cited by this paper
• Ganciclovir implants (Vitrasert).

  1996cited by this paper
• Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

  1995cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Toxicity test of biodegradable polymers by implantation in rabbit cornea.

  1992cited by this paper
• Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema.

  1991cited by this paper
• PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA: EARLY TREATMENT DIABETIC RETINOPATHY STUDY REPORT NO. 4

  1987cited by this paper
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

  1985cited by this paper
• Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules.

  1985cited by this paper

• Switching to subtenon triamcinolone acetonide does not jeopardize the functional and anatomic outcomes of dexamethasone implant treated eyes with diabetic macular edema

  2024cites this paper
• Vitreous inflammatory and angiogenic factors on patients with proliferative diabetic retinopathy or diabetic macular edema: the role of Lipocalin2

  2022cites this paper
• Topical drug delivery to the retina: obstacles and routes to success

  2021cites this paper
• Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization

  2021cites this paper
• Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization

  2021cites this paper
• The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment

  2020cites this paper
• STRUCTURAL AND PHARMACOKINETIC PROPERTIES OF IDI

  2019cites this paper
• Preventing nano and micro wear-particle induced inflammation

  2018cites this paper